Search Results

Keywords: epidiolex

Week in Review: Cannabis layoffs, regulators scrutinizing vitamin E acetate as vape villain, MI adult-use launch looms & more

November 15, 2019 · Updated November 18, 2019

Layoff announcements continue to weigh on the marijuana industry, state regulators focus on vitamin E acetate additive in vaporizer products as the vape crisis continues, Michigan businesses set their game plans for a December adult-use MJ launch, and more of the week’s top cannabis news. Pink slips pile up  Three well-known California cannabis companies this […]

Read More

New UK guidelines recommend public insurance coverage for two GW Pharma cannabis medicines, plus a synthetic cannabinoid

November 12, 2019 · Updated October 13, 2021

New British guidelines for the first time recommend that two plant-based cannabis medicines – Sativex and Epidiolex – be covered through the United Kingdom’s National Health Service (NHS), a significant step that is likely to boost sales of both products. Health regulators also are recommending the NHS make available a synthetic cannabinoid known as nabilone. […]

Read More

Bryant Park Capital CEO Joel Magerman on cannabis investing

November 1, 2019 · Updated June 6, 2021

As CEO of Bryant Park Capital, a New York-based investment bank that provides services to both the cannabis and traditional investment banking markets, Joel Magerman sees cannabis companies showing increased business discipline. And this, he said, is good news for all parties involved. Bryant Park also has a merchant banking affiliate, Emerald Park Capital, that […]

Read More

France appears ready to OK funding for a medical cannabis experiment with 3,000 patients

October 14, 2019 · Updated October 15, 2019

French lawmakers appear ready to approve legislation to bankroll a two-year medical cannabis trial program for 3,000 patients, a move that would give overseas companies the opportunity to export product to what could become one of Europe’s largest markets. Olivier Véran, deputy of the French National Assembly, submitted an amendment to the Social Security Financing Bill (Projet de […]

Read More

Wellness products take off in the growing recreational cannabis market

October 1, 2019 · Updated June 6, 2021

Is the U.S. medical marijuana industry doomed? Amid news reports suggesting that MMJ markets are plateauing or shrinking in some states—particularly those that have approved the recreational use of marijuana, it’s reasonable to believe cannabis executives are bailing out of medical and plowing resources into adult-use products. Not so. Many cannabis companies are doubling down […]

Read More

Are the Feds Changing Their Tune Toward Cannabis?

October 1, 2019 · Updated June 6, 2021

There are growing signs the U.S. Food and Drug Administration (FDA) and federal authorities could be changing their attitudes and policies toward cannabis, potentially paving the way for more studies and additional opportunities for partnerships. Those signs include: Passage of the 2018 Farm Bill legalizing hemp. The FDA’s approval last year of GW Pharmaceuticals’ cannabis-based […]

Read More

Physicians play key role in determining the future of medical marijuana

October 1, 2019 · Updated June 6, 2021

Much of the medical marijuana industry’s future success depends on how seriously the medical community takes the concept of cannabinoids as medicine, and in which form—either as a treatment approved by the U.S. Food and Drug Administration, or one not FDA-approved. By most accounts, physician acceptance and awareness of medical cannabis is growing. But it […]

Read More

Barbados procuring medical cannabis for first imports in April

August 16, 2019

The Barbados Drug Service is inviting companies to submit applications to supply the nation with approved medical cannabinoid products starting April 2020 and lasting through March 31, 2022. The requested products are not legally available in the eastern Caribbean nation at this time. Separately, a bill was introduced in the country’s parliament this week to […]

Read More

‘Pent-up demand’ for FDA-approved cannabis drug boosts UK maker

August 7, 2019 · Updated August 8, 2019

Strong patient interest in the only federally approved CBD product in the United States helped drugmaker GW Pharmaceuticals record $72 million in revenue last quarter. Epidiolex, which is made by London’s GW Pharma (Nasdaq: GWPH), is a seizure control drug approved by the U.S. Food and Drug Administration. It has seen brisk sales and new patient enrollments since the […]

Read More

GW Pharma’s cannabis drug OK’d by European Medicines Agency panel

July 26, 2019 · Updated November 5, 2019

GW Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the British company’s cannabis-based medicine Epidiolex. The CHMP is responsible for preparing the European Medicines Agency (EMA)’s opinions on questions related to the marketing of human medicines. The CHMP opinion was adopted July 25, and the final decision now rests […]

Read More

South Korean medical cannabinoid imports surpass 300 units since law passed

July 25, 2019 · Updated July 26, 2019

South Korea saw just over 300 approved imports of cannabinoid-based medicines in the first few months of the country’s newly regulated medical cannabis program, a volume that underwhelmed local experts who expected demand to be much higher. Almost all the medical cannabis prescriptions were for pure CBD oil. Through July 19, exactly 300 prescriptions had been […]

Read More